Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters

Therapeutic Methods and Therapies TCIM
Database
Language
Affiliation country
Publication year range
1.
Mol Med Rep ; 12(1): 133-40, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25760985

ABSTRACT

Chitosan and Agaricus blazei Murill (ABM) extracts possess antitumor activities. The aim of the present study was to investigate whether chitosan, ABM extract or the two in combination were effective against tumors in tumor­bearing mice. The mice were subcutaneously injected with SK-Hep 1 cells and were then were divided into the following six groups: Group 1, control group; group 2, chitosan 5 mg/kg/day; group 3, chitosan 20 mg/kg/day; group 4, ABM (246 mg/kg/day) and chitosan (5 mg/kg/day) combined; group 5, ABM (984 mg/kg/day) and chitosan (20 mg/kg/day) combined; and group 6, ABM (984 mg/kg/day). The mice were treated with the different concentrations of chitosan, ABM or combinations of the two for 6 weeks. The levels of glutamic oxaloacetic transaminase (GOT), glutamic pyruvic transaminase (GPT) and vascular endothelial growth factor (VEGF), and tissue histopathological features were examined in the surviving animals. Based on the results of the investigation, the treatments performed in groups 2, 3 and 4 were identified as being capable of reducing the weights of the tumors, however, group 4, which was treated with chitosan (5 mg/kg/day) in combination with ABM (246 mg/kg/day) was able to reduce the levels of GOT and VEGF. As a result, treatment with chitosan in combination with ABM may offer potential in cancer therapy and requires further investigation.


Subject(s)
Carcinoma, Hepatocellular/drug therapy , Liver Neoplasms/drug therapy , Plant Extracts/administration & dosage , Severe Combined Immunodeficiency/drug therapy , Agaricus/chemistry , Alanine Transaminase/biosynthesis , Animals , Aspartate Aminotransferases/biosynthesis , Carcinoma, Hepatocellular/pathology , Chitosan/administration & dosage , Chitosan/chemistry , Disease Models, Animal , Gene Expression Regulation, Neoplastic/drug effects , Humans , Liver Neoplasms/pathology , Mice , Mice, SCID , Oligosaccharides/administration & dosage , Oligosaccharides/chemistry , Plant Extracts/chemistry , Severe Combined Immunodeficiency/pathology , Vascular Endothelial Growth Factor A/biosynthesis
2.
Am J Chin Med ; 41(6): 1439-57, 2013.
Article in English | MEDLINE | ID: mdl-24228611

ABSTRACT

Hispolon (a phenolic compound isolated from Phellinus linteus) has been shown to possess strong antioxidant, anti-inflammatory, anticancer, and antidiabetic properties. In this study, we investigated the antiproliferative effect of hispolon on human hepatocellular carcinoma NB4 cells using the MTT assay, DNA fragmentation, DAPI (4, 6-diamidino-2-phenylindole dihydrochloride) staining, and flow cytometric analysis. Hispolon inhibited the cellular growth of NB4 cells in a dose-dependent manner through the induction of cell cycle arrest at G0/G1 phase measured using flow cytometric analysis and apoptotic cell death, as demonstrated by DNA laddering. Exposure of NB4 cells to hispolon-induced apoptosis-related protein expressions, such as the cleavage form of caspase 3, caspase 8, caspase 9, poly (ADP ribose) polymerase, and the proapoptotic Bax protein. Western blot analysis showed that the protein levels of extrinsic apoptotic proteins (Fas and FasL), intrinsic related proteins (cytochrome c), and the ratio of Bax/Bcl-2 were increased in NB4 cells after hispolon treatment. Hispolon-induced G0/G1-phase arrest was associated with a marked decrease in the protein expression of p53, cyclins D1, and cyclins E, and cyclin-dependent kinases (CDKs) 2, and 4, with concomitant induction of p21waf1/Cip1 and p27Kip1. We conclude that hispolon induces both of extrinsic and intrinsic apoptotic pathways in NB4 human leukemia cells in vitro.


Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Antineoplastic Agents, Phytogenic/therapeutic use , Apoptosis/drug effects , Apoptosis/genetics , Catechols/pharmacology , Catechols/therapeutic use , Cell Cycle Checkpoints/drug effects , Cell Cycle Checkpoints/genetics , Leukemia/drug therapy , Leukemia/pathology , Phytotherapy , Polysaccharides/pharmacology , Polysaccharides/therapeutic use , Antineoplastic Agents, Phytogenic/chemistry , Catechols/chemistry , Cell Line, Tumor , Cell Survival/drug effects , DNA Fragmentation/drug effects , Dose-Response Relationship, Drug , Gene Expression Regulation, Developmental/drug effects , Gene Expression Regulation, Developmental/genetics , Gene Expression Regulation, Neoplastic/drug effects , Gene Expression Regulation, Neoplastic/genetics , Genes, Neoplasm/genetics , Humans , Leukemia/genetics , Leukemia/prevention & control , Phellinus , Plant Extracts , Polysaccharides/chemistry
3.
Int J Cancer ; 132(3): 717-25, 2013 Feb 01.
Article in English | MEDLINE | ID: mdl-22736433

ABSTRACT

The use of Salmonella as a potential antitumor agent has been investigated, but innate immunity against this bacterium reduces the efficacy of its tumor-targeting and antitumor activities. The purpose of this study was to investigate the modulation of the tumor-targeting efficiency of Salmonella enterica serovar choleraesuis by modifying the immune response to these bacteria by coating them with poly(allylamine hydrochloride) (PAH), designated PAH-S.C. To evaluate this modulation, we used naïve mice and mice immunized with Salmonella to study the role of the preexisting immune response to the antitumor activity of PAH-S.C. When anti-Salmonella antibodies were present, the invasion activity, cytotoxicity, and gene transfer of Salmonella was significantly decreased, both in vitro and in vivo. Treatment with PAH-S.C. resulted in delayed tumor growth and enhanced survival in immunized mice. Furthermore, immunohistochemical studies of the tumors revealed the infiltration of neutrophils and macrophages in immunized mice treated with PAH-S.C. These results indicate that Salmonella encapsulation effectively circumvented the Salmonella-specific immune response.


Subject(s)
Antibodies, Bacterial/immunology , Macrophages/immunology , Neoplasms, Experimental/microbiology , Neoplasms, Experimental/therapy , Neutrophils/immunology , Salmonella enterica/immunology , Salmonella enterica/physiology , Animals , Antibodies, Neutralizing/immunology , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/therapeutic use , Biological Therapy , Female , Immunization , Mice , Mice, Inbred BALB C , Neoplasms, Experimental/immunology , Polymers
SELECTION OF CITATIONS
SEARCH DETAIL